Oslo HIV cure study group
The Oslo HIV Cure Study Group consists of national and international hematologists, infectious disease specialists, virologists, and immunologists who possess expertise in HIV-1 tropism, reservoirs, and cure research. The following people are part of and contribute in the study group:
Oslo University Hospital and University of Oslo, Norway:
Anders Myhre, Andreas Lindh, Anne Marte Bakken-Kran, Anne-Ma Dyrhol-Riise, Asle Medhus, Azita Rashidi, Bente Halvorsen, Dag Henrik Reikvam, Fredrik Muller, Frode Lars Jahnsen, Hanne Guldsten, Hanne Hestdal Gullaksen, Hans Kristian Aas, Jagiit Singh Bhamra, Magnar Bjørås, Malin Holm Meyer-Myklestad, Mari Kaarbø, Marius Trøseid, Marte Høivik, Mona Holberg-Petersen, Pål Aukrust, Sarah Nur, Tobias Gedde-Dahl, Tuva B Dahl.
Vestfold Hospital, Tønsberg, Norway:
Magnus Moxnes.
Aarhus University Hospital, Århus, Denmark:
Anna Karina Juhl, Astrid Thomsen, Jesper D. Gunst, Katie S. Fisher, Mariane H. Schleimann, Martin Tolstrup, Ole Søgaard.
IrsiCaixa Insitute, Barcelona, Spain:
Gema Fernández Rivas, Irene González Navarro, Javier Martinez-Picado, Maria Salgado Bernal, Victoria González Soler.
Karolinska Institute, Stockholm, Sweden:
Anders Sonnerborg, Piotr Nowak.
Improving prognosis in HIV infection
Translational clinical study of gut mucosal immunology in immunological non-responders people living with HIV. This includes an explorative intervention study on the effects of probiotics. Principal investigator: Malin Meyer-Myklestad. Key collaborators: Hanne Hestdal Gullaksen (PhD fellow), Dag Henrik Reikvam, Asle Medhus, Birgitte Stiksrud, Anne Ma Dyrhol-Riise, Dag Kvale, Ida Gjervol Lunde, Johannes Hov, Martin Kummen, Marius Trøseid, Pål Aukrust, and Mari Kaarbø, all of University of Oslo and Oslo University Hospital.
Gut control of HIV infection
Exploratory intervention trial attempting to transfer beneficial properties from elite controllers HIV to patients with poorer prognosis. Principal investigator: Dag Henrik Reikvam. Key collaborators: Malin Meyer-Myklestad, Asle Medhus, Anne Ma Dyrhol-Riise, Dag Kvale, Ingebjørg Seljeflot, Johannes Hov, Marius Trøseid, Pål Aukrust, and Mari Kaarbø, all of University of Oslo and Oslo University Hospital.
The NLRP3 inflammasome in HIV infection
Exploratory study applying several patient cohorts, testing the potential role of inflammasome activation in relation to HIV progression and comorbidities. Principal investigator: Marius Trøseid. Key collaborators: Hedda Hoel, Pål Aukrust, Johannes Hov, Beate Vestad, Anne Ma Dyrhol-Riise, Dag Henrik Reikvam, and Mari Kaarbø, all of University of Oslo and Oslo University Hospital and Susanne Dam Nielsen, Rigshospitalet University Hospital, Copenhagen.
CoMicS (Copenhagen-Oslo HIV Comorbidity and Microbiota Study)
The largest microbiota study in HIV-infected individuals to date, focusing on the gut microbiota as a potential contributing factor to non-AIDS comorbidities. Principal investigator: Marius Trøseid. Key collaborators: Beate Vestad, Hedda Hoel, Johannes Hov, University of Oslo and Oslo University Hospital, and Susanne Dam Nielsen, Rigshospitalet University Hospital, Copenhagen.
SCRATCH (Microbiota-based SCReening of Anal Cancer in HIV-infected individuals)
A multi-level integrated bioinformatics project in the Era-Net funded SCRATCH consortium, aiming to improve diagnostic screening of HIV-associated anal cancer by microbiota profiles and related metabolites. Principal investigator: Marius Trøseid. Key collaborators: Sajan Raju, Johannes Hov, University of Oslo and Oslo University Hospital, and Sergio Serrano-Villar, Hospital Universitario Ramón y Cajal, Madrid.
EuroSIDA
An international prospective observational cohort study following adult people living with HIV (PLHIV) since 1994. Site prinicipal investigator: Dag Henrik Reikvam. Key collaborators: Anne Ma Dyrhol-Riise, University of Oslo and Oslo University Hospital, and CHIP, Rigshospitalet, University of Copenhagen